Publication: 2833

Publication: 2833

A phase I, open–label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)

URL

URL

Google Scholar

Citation:: Blood vol 130 (Suppl 1) 192

Meeting Instance:: ASH 2017
Year:: 2017
Type:: Abstract
Sub type:: Oral
Funding:: AFT
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3481

Program:: OGC
Primary Committee:: Lymphoma
Sec. Committees:

Pharmas:: Celgene
Grants:

Corr. Author:
Authors:: Peter Martin Nancy L. Bartlett Ildefonso Ismael Rodriguez-Rivera Maria Revuelta Julio C. Chavez John Reagan Sonali M. Smith Ann LaCasce Lei Zhang Merry Zhai Chengqing Wu John Leonard Leandro Cerchietti

Networks:: FL028, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, NEWMEXICO, NY018, RI005

Study: AFT-08
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: CC-486, DLBCL, phase I, R-CHOP